Cyclopharm (ASX:CYC) has spent years as a niche Australian nuclear-medicine company built around a single flagship product, Technegas, an inhaled radioactive agent used to image lung ventilation and help diagnose pulmonary embolism. What makes it one of the more interesting healthcare stories on the ASX is that after decades of use in Australia and dozens of other countries, the company has finally cracked the largest prize of all: United States regulatory approval and a commercial rollout now gathering pace. The half-year result released on 24 August 2026 offered a fresh read on how that expansion is tracking.

For a company of this size, the US opportunity is potentially transformational, and the numbers are beginning to reflect early traction rather than just promise.

A record half, led by the US

Cyclopharm reported total Revenue of about AUD 17.5 million for the six months to 30 June 2026, up roughly 14% and described as its fifth consecutive record revenue half. The standout was the United States, where Technegas revenue surged about 74% to around AUD 2.1 million from AUD 1.2 million a year earlier. While still a small absolute contribution, that growth rate signals accelerating adoption in a market many times the size of Cyclopharm's established territories.

The rollout is measured in installed, revenue-generating sites. The company had grown to about 70 revenue-generating US locations by mid-2026, up from around 50 previously, as it works through a large pipeline of hospitals and imaging centres.

The guidelines catalyst

A key strategic point management emphasised is that US growth to date has occurred without the benefit of newly published international lung-imaging clinical guidelines. Those guidelines, which reference ventilation imaging, are viewed as a potential accelerant for clinical adoption. Their timing has also influenced Cyclopharm's own targets: the company extended the horizon on its goal of reaching roughly 250 to 300 US revenue-generating sites beyond the end of the 2026 calendar year, attributing the pushout partly to the pending publication of those guidelines.

That is the double-edged nature of the story. The long-term site target underscores the scale of the opportunity, but the extended timeline is a reminder that clinical rollouts move slowly and depend on factors outside the company's control.

Financial position and what to watch

Encouragingly, Cyclopharm indicated it had passed peak cash burn as Recurring Revenue expanded, and held about AUD 12.2 million in cash at 30 June 2026. For a commercialising medical-device business, moving past peak burn is an important marker on the path toward self-funding growth.

Investors will watch the pace of new US site additions in coming updates, the eventual publication and clinical uptake of the lung-imaging guidelines, the trajectory of recurring US revenue, and the cash position to gauge whether further funding might be required. Progress in Cyclopharm's established markets and any regulatory expansion of indications are secondary watch points.

Risks to weigh

The risks are meaningful. Cyclopharm remains highly dependent on a single product and on the success of one market entry; delays in the US rollout or in the supporting guidelines would push out the payoff. The cash balance, while improved, is modest relative to the ambition, raising the prospect of a future raise if growth requires more investment. Reimbursement dynamics, competition in lung imaging, and the operational challenge of scaling site installations all bear on the outcome.

On balance, Cyclopharm has moved from a long-awaited approval into genuine early commercial momentum in the US, with record group revenue and a Business that has passed peak cash burn. The extended site-target timeline tempers the near-term enthusiasm, but the combination of a large addressable market, accelerating US revenue and a potential guidelines catalyst is what keeps it among the more closely watched small-cap healthcare names on the ASX.